First human test of cell therapy for critically ill COVID patients
NCT ID NCT04582201
Summary
This early-stage study tested the safety of a new cell-based treatment called agenT-797 in 20 hospitalized COVID-19 patients with severe lung failure who needed a ventilator. The goal was to see if infusing these special immune cells could help control the disease and improve outcomes. Researchers primarily monitored for side effects while also tracking measures like how long patients needed breathing support.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY DISTRESS SYNDROME, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Norton Cancer Institute, St. Matthews Campus
Louisville, Kentucky, 40207, United States
-
Saint John's Cancer Institute
Santa Monica, California, 90404, United States
-
Weill Cornell Medicine New York Presbyterian
New York, New York, 10022, United States
Conditions
Explore the condition pages connected to this study.